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Abstract
Objective: CYP11A1 mutations cause P450 side-chain cleavage (scc) deficiency, a rare form of congenital adrenal 
hyperplasia with a wide clinical spectrum. We detail the phenotype and evolution in a male sibship identified by 
HaloPlex targeted capture array.
Family study: The youngest of three brothers from a non-consanguineous Scottish family presented with 
hyperpigmentation at 3.7 years. Investigation showed grossly impaired glucocorticoid function with ACTH elevation, 
moderately impaired mineralocorticoid function, and normal external genitalia. The older brothers were found to be 
pigmented also, with glucocorticoid impairment but normal electrolytes. Linkage studies in 2002 showed that all three 
brothers had inherited the same critical regions of the maternal X chromosome suggesting an X-linked disorder, but 
analysis of NR0B1 (DAX-1, adrenal hypoplasia) and ABCD1 (adrenoleukodystrophy) were negative.
In 2016, next-generation sequencing revealed compound heterozygosity for the rs6161 variant in CYP11A1 (c.940G>A, 
p.Glu314Lys), together with a severely disruptive frameshift mutation (c.790_802del, K264Lfs*5). The brothers were 
stable on hydrocortisone and fludrocortisone replacement, testicular volumes (15–20 mL), and serum testosterone 
levels (24.7, 33.3, and 27.2 nmol/L) were normal, but FSH (41.2 µ/L) was elevated in the proband. The latter had 
undergone left orchidectomy for suspected malignancy at the age of 25 years and was attending a fertility clinic for 
oligospermia. Initial histology was reported as showing nodular Leydig cell hyperplasia. However, histological review 
using CD56 staining confirmed testicular adrenal rest cell tumour (TART).
Conclusion: This kinship with partial P450scc deficiency demonstrates the importance of precise diagnosis in primary 
adrenal insufficiency to ensure appropriate counselling and management, particularly of TART.
Established facts
 • Primary adrenal insufficiency (PAI) is a life-threatening 
disorder of the adrenal cortex, characterised by 
impaired production of glucocorticoids with or 
without deficiency in mineralocorticoids and adrenal 
androgens.
 • Classic CYP11A1 mutation causes under-
androgenisation in affected 46,XY subjects and severe 
salt-wasting in both 46,XY and 46,XX individuals due 
to disruption of the P450 side-chain cleavage (P450scc) 
enzyme.
Correspondence 
should be addressed 
to M Donaldson 
Email 
malcolm.donaldson@
glasgow.ac.uk
European Journal of 
Endocrinology  
(2020) 182, K15–K24
-19-0696
Case Report
182
3
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Printed in Great Britain
Published by Bioscientifica Ltd.
© 2020 The authorshttps://eje.bioscientifica.com
https://doi.org/10.1530/EJE-19-0696
Downloaded from Bioscientifica.com at 04/24/2020 02:46:27PM
via free access
Eu
ro
pe
an
 Jo
ur
na
l o
f E
nd
oc
ri
no
lo
gy
182:3 K16Case Report W Kallali and others Partial P450 scc deficiency in a 
male sibship
https://eje.bioscientifica.com
 • Partial P450scc deficiency presents with late-onset 
primary adrenal insufficiency (PAI) without genital 
anomalies.
 • Partial P450scc deficiency is emerging as a surprisingly 
common cause of previously undiagnosed PAI.
Novel insights
 • P450scc deficiency was discovered only in adulthood 
in three brothers who had presented during 
childhood with glucocorticoid deficiency, modest 
mineralocorticoid impairment, and intact Leydig cell 
function and who had been labeled as having PAI of 
unknown cause.
 • One sibling had undergone radical left orchidectomy 
at 25 years for suspected malignancy. Histology had 
initially been reported as ‘Leydig cell hyperplasia’, but 
the diagnosis was revised to testicular adrenal rest cell 
tumour (TART) in the light of the recent diagnosis of 
P450scc deficiency, with positive CD56 staining in 
adrenal rest cell nodules and clumps, but not in the 
Leydig cells.
 • This sibship highlights the importance of considering 
rare forms of congenital adrenal hyperplasia in the 
differential diagnosis of adrenal insufficiency.
Introduction
The term primary adrenal insufficiency (PAI) describes 
a group of potentially life-threatening disorders, either 
congenital or acquired, in which an intrinsic defect 
results in impaired cortisol synthesis. The term ‘Addison’s 
disease’ is often used as a synonym for PAI, although 
Addison’s original paper described adrenal failure in six 
patients with tuberculosis, hence, some workers reserve 
the term for acquired PAI (1).
Congenital PAI is usually due to monogenic causes (2, 
3). Principal causes include congenital adrenal hyperplasia 
(CAH), X-linked congenital adrenal hypoplasia due to 
disruptions in NR0B1 (DAX-1), familial glucocorticoid 
deficiency (FGD) and related ACTH-resistance conditions, 
X-linked adrenoleukodystrophy (ALD), and Allgrove 
syndrome (Triple A syndrome).
Acquired PAI is usually due to autoimmune adrenalitis, 
either alone or in combination with other autoimmune 
disorders (2, 4, 5, 6, 7). Tuberculous destruction of 
the adrenal glands remains an important cause of PAI 
worldwide (8).
Recent advances in genetic investigations have 
contributed to the determination of the underlying 
etiology in more than 80% of children with PAI 
(9, 10, 11).
Recently, there has been growing interest in PAI due 
to one rare form of CAH – cholesterol side-chain cleavage 
enzyme or P450scc deficiency. The P450scc enzyme 
plays a key role in the initial steps of steroidogenesis by 
catalyzing the conversion of cholesterol to pregnenolone 
in steroidogenic tissues such as the adrenal gland and 
gonads and is encoded by the CYP11A1 gene, localized on 
chromosome 15q23-q24 (12).
P450scc deficiency (OMIM 613743) causes impaired 
production of gonadal and adrenal steroids and may 
result in complete or partial adrenal insufficiency with 
a wide range of clinical manifestations. To date, fewer 
than 40 patients with P450scc deficiency have been 
reported. Classic deficiency presents with severe early-
onset adrenal insufficiency in the neonatal period and 
female external genitalia in 46,XY individuals (11, 13, 
14, 15, 16, 17, 18, 19). Partial defects result in late-onset 
adrenal insufficiency or glucocorticoid insufficiency 
alone, associated with either normal genitalia or variable 
degrees of underandrogenisation (11, 15, 19, 20, 21, 22, 
23, 24, 25).
Recently, Maharaj and colleagues reported that the 
missense mutation rs6161, c.940G>A, p.Glu314Lys, 
previously predicted to be a benign variant, results in 
PAI in the context of compound heterozygosity when 
combined with variations harboring disruptive changes 
(26). In all, 28 cases of P450scc deficiency related to the 
presence of the rs6161, c.940G>A, p.Glu314Lys variant 
have been described, 19 by Maharaj et al (26) and 9 from 
other centres (19, 24, 25).
In this report, we detail the diagnosis and outcome 
in Family 8 of the Maharaj paper, comprising three 
brothers, one of whom developed testicular adrenal rest 
tumor (TART). We also explore the question of gonadal 
impairment in P450scc deficiency, particularly relating 
to fertility.
Patients and methods
Figure 1A shows three generations of a Scottish family 
featuring the father (I-1), and mother (I-2), their five 
children – two daughters (II-1 and II-4), three sons (II-2, 
II-3, II-5), and the offspring of the II-1 and II-4.
DNA was collected from both parents and all five 
children in 2002, following written informed consent in 
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order to carry out X-linkage studies and DAX-1 analysis. 
The remaining DNA was subsequently stored.
In 2016, a consent was obtained once again from the 
five children, the parents being now deceased, for further 
molecular genetic analysis on the already stored DNA. 
Next-generation sequencing studies were performed as 
part of an initiative to assess the prevalence of CYP11A1 
deficiency in PAI in 2016. In this study, HaloPlex targeted 
Gene Panel analysis was performed as described (26).
Following this, consent was obtained from II-5 for 
information on testicular surgery and fertility treatment 
in separate hospitals outside Scotland to be gathered. 
Finally, DNA from I-1 and II-4 were reanalyzed in 2019 
after further DNA had been sent from Glasgow, since the 
previous sent samples had been insufficient. Testing of the 
third generation was not undertaken.
Family study
Childhood presentation
The proband (II-5) was born at 38 weeks of gestation by 
caesarean section for placental abruption weighing 2.84 
kg and presented initially with poor feeding and weight 
faltering at 5 months. He was then admitted collapsed, 
mottled and cyanosed at the age of 21 months with a 
1-day history of diarrhoea and fever. On examination, 
weight was 7.8 kg, s.d. was 4.31 below the mean, length 
was 75 cm (−2.95 s.d.). Investigations showed normal 
sodium (138 mmol/L) and potassium (3.9 mmol/L), with 
a compensated metabolic acidosis (pH 7.38, bicarbonate 
13 mmol/L, base excess −15) and hypoglycaemia (blood 
glucose 1.6 mmol/L). A clinical diagnosis of septicaemia 
was made. He was given 10% dextrose with 1/5th 
normal saline at 50 mL/h initially (10.7 mg/kg/min of 
glucose) after which no further hypoglycaemia occurred. 
He was ventilated for 12 days, given Cefotaxime and 
Metronidazole, and fluid support with Dopamine but 
did not receive steroids at any point. He had an acute 
respiratory distress syndrome with left pneumothorax but 
went on to make a full recovery and was discharged at 
6 weeks. Blood cultures and viral studies were negative. 
He was readmitted shortly after this with cough and fever 
(38.6°C) accompanied by a 1-min episode of stiffness, 
staring and unresponsiveness (Table 1).
At the age of 3.7 years, the child was admitted with 
fever (39.5°C) and tonsillitis associated with a 15-min 
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Figure 1
(A) Family tree of three generations in a non-consanguineous 
Scottish kinship with CYP11A1 deficiency affecting three 
brothers. The father carries a disruptive variant (c.790_802del, 
K264Lfs*5), while the mother is a carrier for a relatively 
common variant (c.940G>A, p.Glu314Lys) which was 
previously predicted as benign but which has been found to 
affect splicing. All brothers are compound heterozygotes, one 
sister is a carrier for c.790_802del mutation and the other is 
unaffected. None of the third generation has been tested. (B) 
X-linkage studies in a kinship with primary adrenal 
insufficiency indicating that the three affected brothers had 
inherited the same maternal X chromosome, suggesting an 
X-linked disorder. Subsequently, the brothers were found to 
be compound heterozygotes for CYP11A1 deficiency, inherited 
in autosomal recessive fashion. (C) Chromatogram showing 
paternally inherited c.790_802del, K264Lfs*5 and maternally 
inherited c.940G>A, p.Glu314Lys changes in CYP11A1, resulting 
in P450 side-chain cleavage enzyme deficiency.
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tonic-clonic convulsion. On this occasion he was noted 
to be pigmented and investigations showed a flat cortisol 
response to a synthetic ACTH (Synacthen) test under 
fasting conditions, with elevated renin at 1209 μIU/mL 
(normal <50) and ACTH at 1089 mU/L (normal <20), and 
hyponatraemia (128 mmol/L) (Table 1) indicating primary 
adrenal insufficiency. Blood glucose was 2.8 mmol/L. 
He was started on treatment with Hydrocortisone and 
Fludrocortisone (Table 1).
Two further acute admissions while on steroid 
replacement occurred at the age of 4.5 and 5.7 years, both 
featuring fever and convulsions, with normal electrolytes 
and glucose (4.3 mmol/L) on the first occasion.
At the time the proband was diagnosed with PAI, both 
brothers were also noted to be pigmented. Synacthen 
tests were performed, therefore, which confirmed PAI 
(Table 1). Electrolytes were not recorded at this time. 
Subsequent electrolytes did not show hyponatraemia or 
hyperkalaemia but subsequent ACTH and renin values 
while on treatment showed elevation: renin 73 μU/mL 
and ACTH 1532 mU/L for II-2; and renin 120 μIU/mL and 
ACTH 66 mU/L (suspected degradation of sample) for II-3.
None of the brothers showed evidence of salt-craving 
although the family diet was noted to be high in crisps.
Family history
Parents were non-consanguineous. I-1 had undergone 
valve replacement for aortic valve disease. I-2 experienced 
convulsions in childhood until the age of 7, suffered from 
alcohol dependency, and was judged to have a degree of 
learning impairment.
II-1 and II-4 were both born at 40 weeks, weighing 
3.1 and 2.6 kg. II-1 had a history of febrile convulsion at 
the age of 2 years and has developed aortic valve disease 
requiring replacement in adult life.
II-2 had several convulsions with fever in early 
childhood and was treated with phenobarbitone. He was 
hypotonic in infancy and showed developmental delay, 
not walking until 3 years or speaking clearly until 5 years 
of age.
II-3 had been hospitalized after birth for respiratory 
distress and hyperbilirubinemia. He was hypotonic with 
delayed motor milestones. At the age of 3 years he had 
a 30-min convulsion (temperature 38.2°C) and a further 
2-min fit with fever at the age of 4 years.
Both II-2 and II-3 had tested negative for Fragile X 
syndrome and Duchenne muscular dystrophy. Both 
brothers were attending the same special educational 
needs school at the time II-5 was diagnosed.
Child and adolescent follow-up
None of the brothers were hospitalized for acute 
adrenal insufficiency. A target glucocorticoid dose of 
hydrocortisone 12 mg/m2/day was given and then 
adjusted according to clinical features including general 
health and well-being, growth rate, and BMI. As shown 
Table 1 Details of childhood presentation, treatment and pubertal status in three brothers with partial P450scc deficiency due 
to a CYP11A1 mutation (rs6161 variant (c.940G>A, p.Glu314Lys) affecting splicing and another disruptive variant causing 
frameshift and premature stop codon (c.790_802del, K264Lfs*5)).
II-2 II-3 II-5
Birth year 1979 1980 1985
Birthweight (kg) 2.6 2.52 2.84
Gestation (weeks) 40 40 38
Age at diagnosis (years) 8.9 8 3.7
Height (cm) (SDS) at diagnosis 125 (−1.3) 117 (−2.0) 94 (−1.5)
Weight (kg) (SDS) at presentation 22 (−1.78) 18.5 (−2.67) 13.8 (−1.13)
Initial investigations
 Basal/peak cortisol (nmol/L) 278/289 339/389 174/178
 Lowest plasma sodium (mmol/L) 137 138 128
 Highest plasma potassium (mmol/L) 4.7 4.2 5.9
 ACTH (mU/L) (n < 20) N/A N/A 1089
 Renin (µIU/mL) NR (9–50) N/A N/A 1209
Maintenance treatment one year after diagnosis
 Hydrocortisone (mg/m2/day) 12 21.5 16.6
 Fludrocortisone (µg/day) 100 100 100
Growth and pubertal status
 Age at G2 13 years 14 years 12 years
 Age at G4 15.8 16.0 14.1
 Testicular volume at G5 12–15 mL 12–15 mL 15 mL
 Final height (cm)(SDS) 171 (−0.8) 168 (−1.2) 171 (−0.8)
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in Table 1, II-2 was receiving the expected glucocorticoid 
dose after 1 year, whereas the hydrocortisone doses in II-5 
and II-3 had been increased on clinical grounds, for example, 
thin build – to 16.6 and 21.5 mg/m2/day respectively. 
II-3 remained deeply pigmented throughout childhood 
and adolescence despite receiving a supraphysiological 
replacement dose and parental assertion that he was 
the better tablet-taker of the three brothers.
Linear growth was satisfactory in all three brothers 
and all completed puberty with normal testicular 
volumes, although II-2 and II-3 entered puberty 2 years 
later than average. BMI values were 15.96, 15.3, and 15.44 
kg/m2 for II-2, II-3, and II-5 at 12 years of age, indicating 
that a low BMI was not responsible for the pubertal delay 
in II2 and II-3. In fact, the elder brothers had higher BMI 
than II-5 at 14 years of age – 18.82, 17.45, and 14.38 kg/
m2, respectively. Final heights were in the lower half of 
the parental target range – mid-parental height 174.5 cm 
(−0.3 SDS) (Table 1).
Initial genetic studies (2002)
Because of the likelihood of an X-linked disorder affecting 
the three brothers, markers were used to determine which 
X-chromosome had been inherited by each member 
of the second generation. Four overlapping primer sets 
covering the two exons of the NR0B1 (DAX-1) gene were 
then used to sequence the middle brother’s DAX-1 gene: 
DX1, DX2, DX3, and DX4. Figure 1B shows that all three 
brothers and the sibling II-4 have inherited the same 
maternal sex chromosome. In the light of the clinical 
presentation, family pattern and X-linkage findings, 
X-linked PAI was considered likely but genetic analysis 
for NR0B1 (DAX-1) was negative, while very long chain 
fatty acid and studies were normal, excluding X-linked 
adrenoleukodystrophy. Genetic studies were also carried 
out in Germany (Professor Angela Hübner, Children’s 
Hospital, Medical Faculty, Technical University Dresden, 
Germany) to exclude Triple A syndrome and showed 
normal results.
Adult outcome
In 2016, Haloplex genetic analysis revealed compound 
heterozygosity of the CYP11A1 gene with a disruptive 
variant causing frameshift and premature stop codon 
(c.790_802del, K264Lfs*5) and another relatively 
common variant rs6161 (c.940G>A, p.Glu314Lys) which 
was previously predicted ‘benign’ but was found to affect 
splicing (Fig. 1C).
The elder sister II-1 had developed aortic valve disease 
requiring replacement as had a paternal half-brother. It 
was noted that brothers II-2 and II-3 were suffering from 
alcohol dependency and that II-3 was receiving treatment 
for epilepsy with slow-release Sodium valproate.
Clinical and laboratory assessment of the three brothers
At clinical review aged 32, 36, and 37 years, the 
brothers were noted to be stable on hydrocortisone and 
fludrocortisone replacement. Glucocorticoid doses were 
high – 17.3, 18.6, and 24.6 mg/m2/d – but with no clinical 
features to indicate overreplacement, slight pigmentation, 
and normal BMI (Table 2).
There was scanty body hair but normal pubic hair, 
normal testicular volumes (15–20 mL), and normal serum 
testosterone. However, FSH values were borderline high 
in II-2 and frankly elevated in II-5. Samples for Inhibin 
B measurement were received by the laboratory but not 
analysed, owing to a system failure.
It also transpired that the proband (II-5) had presented 
to a hospital outside Scotland during the previous year with 
a 4-year history of left testicular swelling and discomfort. 
Review of medical records indicated that ultrasound had 
shown bilateral varicoceles, a left epididymal cyst, and a 
suspicious 6 × 7 mm mass at the upper of the left testis. 
Testicular tumour marker lactic dehydrogenase was 600 
µ/L (reference range 256–500). At a multidisciplinary 
meeting, the diagnosis of ‘Addison’s disease’ was noted 
and radical left inguinal orchidectomy was scheduled. 
The initial histology report indicated ‘nodular Leydig cell 
hyperplasia.’
After review in 2017, II-3 died during an epileptic 
convulsion which followed a 48-h period of binge 
drinking. Post-mortem examination was not requested by 
the Procurator Fiscal.
In 2019, the hospital responsible for II-5’s 
orchidectomy were contacted and asked to review the 
testicular histology. Figure 2A and B show nodules of 
TART on H&E low power. Staining with Inhibin (Fig. 2C) 
is non-specific. However, staining with CD56 (neural 
cell adhesion molecule 1) (Fig. 2D) shows patchy uptake 
in the nodules and in clumps of lipid-laden interstitial 
cells, but no uptake by seminiferous tubules or Leydig 
cells, consistent with nodules and clumps of adrenal rest 
cells. A Johnsen count performed on the spermatozoa on 
histology showed a reduced score of 7.5 – normal adult 
score 8.9 (27) – indicating decreased spermatogenesis.
II-5 retrospectively rated his adherence with 
hydrocortisone and fludrocortisone since childhood as 
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very poor from 12 to 17 years of age, patchy from 17 to 29 
years, and good during the previous 3 years.
Further enquiry revealed that II-5 and his partner 
had been trying for a baby for 4 years and had attended 
a fertility center for assessment. Semen analysis had 
shown reduced sperm concentration – 2.0 million per mL 
(normal 15), reduced sperm count at 8 million (normal 
39 million per ejaculate), reduced motility with 77% 
immobile and 18% progressive (normal ≥40% motile and 
≥32% progressive), and reduced normal forms. The couple 
had been enrolled into an in vitro fertilisation programme.
Discussion
This sibship demonstrates a relatively mild phenotype 
of CYP11A1 deficiency with late presentation, dominant 
glucocorticoid deficiency, mild mineralocorticoid 
deficiency, no disorder of sex development, and intact 
Leydig cell function.
It is hard to assess the clinical contribution of CYP11A1 
deficiency to the sibship prior to diagnosis, given that 
features such as convulsions and learning difficulties had 
affected other family members. Although it is possible 
that the severity and duration of the proband’s acute 
illness requiring ventilation might have been worsened 
by the adrenal insufficiency, the fact that he recovered 
fully without steroid support indicates that this was not 
the primary cause.
The partial nature of P450scc deficiency in this family 
is consistent with most of the published cases with similar 
genetic findings (19, 24, 25, 26).
In the context of the three affected brothers, two of 
whom had learning difficulties, two unaffected sisters, 
a mother with probable learning difficulties, and the 
finding of inheritance of the same X chromosome in 
Table 2 Data of three adult brothers with CYP11A1 mutation (rs6161 variant (c.940G>A, p.Glu314Lys) affecting splicing and 
another disruptive variant causing frameshift and premature stop codon (c.790_802del, K264Lfs*5)).
II-2 II-3 II-5
Age at evaluation (years) 37.3 36.4 31.6
Weight (kg) 65.6 58.3 58.5 
BMI (kg/m2) 22.4 20.6 20
Blood pressure (mm Hg) 112/66 152/94 106/58
Tanner stage
Testicular volumes R/L
G5P5
20/20
G5P5
15/15
G5P5
20/–
Investigations
 Basal FSH IU/l (1–12) 13.8 9.3 41.2
 Basal LH IU/l (0.6–12.1) 5.8 5.4 33.9
 Serum testosterone (nmol/L) (8.3–33) 24.7 33.3 6
 ACTH (mU/l) (<20) 1532 43 1267
 Renin (ng/mL/h) (<2.6) 12.6 13.2 27.2
Maintenance treatment
 Hydrocortisone, mg (mg/m2/day) 30 (17.3) 30 (18.6) 40 (24.6)
 Fludrocortisone (µg/day) 100 100 200
 Adherence Good (6/7 days) Moderate (forgets most mornings) Poor until 2 years ago (see text)
Hormone reference ranges for Queen Elizabeth Glasgow Hospitals is given in brackets. Please see Table 1 for final height data.
A
TART
TART
TART
TART
LC
ST
L-LC
B
C D
ARCST
Figure 2
Testicular histology following radical orchidectomy for 
suspected malignancy in a subject with testicular rest cell 
tumour (TART) secondary to poorly controlled congenital 
adrenal hyperplasia due to CYP11A1 deficiency. Staining with 
haematoxylin and eosin (A and B) shows the nodules of TART. 
Inhibin staining (C) is positive for TART but also Leydig cells 
(LC), seminiferous tubules (ST), and lipid-laden cells (L-L C), 
believed to be adrenal rest cells. Staining with CD56 (D) shows 
uptake by some cells in the TART nodule and adrenal rest 
clumps (ARC) but not the Leydig cells or seminiferous tubules.
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the three siblings, it is understandable that an X-linked 
disorder akin to DAX-1-associated adrenal hypoplasia 
was thought likely. In fact, the cause was an autosomal 
recessive disorder, and it was purely by chance that only 
the males were affected. The probability of all three boys 
and neither of the two girls being affected with P450scc 
deficiency is calculated at just under 1% – unlikely but not 
extremely unlikely – indicating that X-linked inheritance 
should not be assumed when only males are affected.
Glucocorticoid deficiency was the dominant feature 
of PAI in this sibship. All three brothers were significantly 
pigmented at presentation, with no significant rise in 
baseline cortisol levels after synthetic ACTH stimulation, 
indicating markedly impaired glucocorticoid synthesis 
and elevated ACTH levels, even in the absence of actual 
ACTH measurement at baseline in II-2 and II-3. The 
modest ACTH elevation seen thereafter in the older 
brothers, despite significant pigmentation, could reflect 
the problems with sample degradation which were 
encountered in our hospital in the late 1980s and early 
1990s. Furthermore, ACTH concentrations may also 
vary considerably in the same individual, depending on 
when the hydrocortisone was taken and when the blood 
collection took place.
High hydrocortisone doses were given to the middle 
brother (II-3), who was always deeply pigmented and thin 
as if undertreated, and to the proband (II-5) who went 
on to develop TART. The doses administered (Table 1) 
considerably exceed the 10–12 mg/m2/day recommended 
in PAI (28). It should be noted that the degree of 
pigmentation is of limited usefulness as an index of 
cortisol replacement therapy and that over-reliance on 
this marker risks overtreatment, although this was not the 
case in our patients.
While poor compliance might seem an obvious 
explanation for the high hydrocortisone requirement, 
and was acknowledged by II-5 to have been very poor in 
adolescence and early adult life, the parents claimed good 
compliance during the childhood years; a view confirmed 
by the four siblings at interview in 2019 after II-3’s death. 
There is, therefore, no satisfactory explanation for this 
observation. It should be noted that persistently elevated 
ACTH can be seen in familial glucocorticoid deficiency 
(e.g. due to MC2R or ACTH receptor mutations) and 
attempts to suppress this with high replacement doses can 
potentially cause signs of glucocorticoid excess. However, 
this was not the case in II-3, who had a persistently 
low BMI.
By contrast, mineralocorticoid deficiency was mild 
in the sibship. Hyponatraemia was only recorded once 
– in the proband when he presented with a septicaemia-
like illness. On this occasion, the sodium value of 
128 mmol/L may not have been purely related to salt 
loss, and glucocorticoid deficiency per se may result in 
hyponatraemia by reducing water excretion (29). However, 
renin levels were elevated even on treatment in the 
patients, and crisps formed an important part of the diet. 
It could be argued that a smaller dose of mineralocorticoid 
could have been given, but it is our policy to give a full 
replacement dose of fludrocortisone, even with subclinical 
aldosterone deficiency to ensure adequate replacement, 
being prepared to reduce this in the event of hypertension 
and/or hypokalaemia, neither of which occurred.
Consistent with previous reports, pubertal 
development (although delayed in the two older brothers) 
was normal in the sibship, with normal testicular volumes 
and Leydig cell function (19, 24, 25, 26).
However, long-term follow-up has demonstrated 
abnormal germ cell function in the proband with FSH 
elevation, oligozoospermia, and reduced sperm motility. 
FSH elevation is probably related to disturbed Sertoli cell 
function secondary to development of TART (30, 31, 32), 
on a background of many years during which adherence 
to steroid therapy was poor.
TART is well described as a feature of poorly controlled 
21-hydroxylase deficiency, the most common form of 
CAH (32, 33). Of note, angiotensin II receptors are found 
in TART tissue, so that mineralocorticoid deficiency, in 
addition to glucocorticoid deficiency, may contribute to 
its development (33).
However, factors other than poor hormonal control 
have been implicated in the development of TART; 
these include testicular ‘misplacement’ of adrenal cells 
during development, with prenatal exposure to increased 
ACTH levels, and the presence of pluripotent cells which 
can differentiate into adrenocortical cells after ACTH 
stimulation (34, 35).
TART has also been described in conditions other 
than 21-hydroxylase deficiency, with reports of this 
complication in rarer forms of CAH such as 11-hydroxylase 
deficiency and 3β-hydroxysteroid dehydrogenase type 2 
deficiency but not in autoimmune PAI (32, 33).
There is only one previous report of TART in two 
peripubertal male patients with CYP11A1 deficiency (25). 
The diagnosis in these two reported patients was made by 
ultrasound, which is the preferred method of detection 
(33), while there are both ultrasound and histological data 
in the case we describe.
Our case demonstrates the histological features of 
adrenal rest cells in the removed testis and shows that the 
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CD56 stain was the most discriminating in demonstrating 
that the cells in the nodules and the clumps of interstitial 
cells were adrenal in origin. By contrast, Inhibin staining 
was less specific for adrenal tissue while Melan staining 
did not identify the clumps of adrenal rest cells (data not 
shown). The CD56 findings are similar to that described by 
Ali et al. in which a 15-year-old boy with 21-hydroxylase 
deficiency underwent bilateral orchidectomy, the adrenal 
rest tissue showing strong staining for both CD56 and 
synaptophysin (36). Of note, CD56 staining demonstrated 
lipid-laden cells in our case. While macrophages may stain 
similarly, the site of these cells in the context of CYP11A1 
deficiency strongly suggests that these are adrenal in 
origin. The increased lipid content is consistent with the 
proximal adrenal enzyme block and analogous to STAR 
protein deficiency. Consistent with this, a previous study 
in Cyp11a1-null mice demonstrated lipid accumulation in 
fetal adrenals, leading to the degeneration of adrenocortical 
cells soon after these cells had differentiated (37).
Reduced fertility is a recognised consequence of 
inadequately controlled 21-hydroxylase deficiency with 
TART formation but has not previously been documented 
in P450scc deficiency. It is likely that the fertility problems 
in our patient are related to TART with the impairment in 
sperm production, as indicated by the reduced Johnsen 
count, consistent with a toxic paracrine effect of the steroid 
hormones or metabolites produced by the adrenal rests 
as in 21-hydroxylase deficiency (32, 33, 38). A reduction 
in sperm count could also result from obstruction caused 
by the nodules and adrenal rest clumps compressing 
the rete testis and seminiferous tubules (32, 33, 38). 
Another possible explanation is that lipid accumulation 
in steroidogenic cells could also be an additional factor 
of reduced spermatogenesis, similar to previous reports of 
patients with STAR protein deficiency (39).
The missed diagnosis of TART as the cause for 
testicular swelling in the younger brother relates to the 
lack of a specific diagnosis for his PAI at the time of 
presentation with testicular discomfort and left testicular 
swelling. Had the specific diagnosis been reached 
earlier, surgery would not have been the treatment 
of choice. Intensifying glucocorticoid treatment may 
improve testicular function in the early stages of TART 
by suppressing ACTH secretion leading to reduction of 
the tumour size (32, 33). Regular monitoring of these 
patients with ultrasound is also recommended to make 
an early diagnosis and offer patients with TART semen 
cryopreservation. Surgery is only indicated to relieve 
pain and discomfort in patients with TART and does not 
restore fertility (32, 33).
This case of P450scc deficiency and previous reports 
on fertility in patients with CAH due to 21 hydroxylase 
deficiency and StAR protein deficiency (31, 40) reinforces 
the importance of early diagnosis. Timely diagnosis 
ensures that gonadal function will be monitored in the 
long term, with a view to optimizing fertility and offering 
treatment, including sperm banking in progressive cases. 
In established cases, serial LH, FSH, testosterone, Inhibin 
B, and semen analysis should be recommended regularly 
in addition to clinical examination and serial testicular 
ultrasounds for adrenal rests (31, 32, 40).
Finally, PAI should be regarded as a descriptive 
diagnosis requiring a specific explanation. We caution 
against using the term ‘Addison’s disease’ in congenital 
PAI, since this implies a valid diagnosis. Had the problem 
in our proband been listed as ‘congenital primary adrenal 
insufficiency of unknown cause’, a link between the 
adrenal and his testicular problem might have been 
considered and a change in management might have 
been brought about.
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